This article was originally published in The Gray Sheet
Executive SummaryAnti-microbial, peripherally inserted central catheter will debut in the U.S. in the fourth quarter following receipt of 510(k) clearance, announced Sept. 7. The ArrowEvolution PICC with Chlorag+ard technology has a chlorhexidine-based solution bonded to the catheter's surface. The firm says the anti-microbial coating will help health care providers protect against central line-associated bloodstream infections. The product complements Teleflex's currently available Arrowg+ard Blue Plus acute central venous catheter with chlorhexidine
You may also be interested in...
US FDA usually recommends using overall survival for pancreatic cancer drugs, but AstraZeneca choose progression-free survival; now ODAC will weigh in on whether the PARP inhibitor olaparib demonstrated a clinically meaningful impact. The firm cites enrollment and design challenges in the gBRCAm population as reasons for using PFS.
Attorneys say Sarepta did not have an obligation to report its appeal, particularly since winning a formal dispute filing with the US FDA is a long shot.